Bone Research · 2019 · 499 citations · 176 references
Life SciencesImmunologyOrthopedic SurgeryAutoimmunityInnate ImmunityRheumatologyAnkylosing SpondylitisAutoimmune InflammationAutoimmune Rheumatic DiseasesCytokine BiologyInflammatory ProcessesJoint DiseaseHuman Leukocyte Antigen B27Innate Immune Cytokines
Ankylosing spondylitis (AS), a common type of spondyloarthropathy, is a chronic inflammatory autoimmune disease that mainly affects spine joints, causing severe, chronic pain; additionally, in more advanced cases, it can cause spine fusion. Significant progress in its pathophysiology and treatment has been achieved in the last decade. Immune cells and innate cytokines have been suggested to be crucial in the pathogenesis of AS, especially human leukocyte antigen (HLA)‑B27 and the interleukin‑23/17 axis. However, the pathogenesis of AS remains unclear. The current study reviewed the etiology and pathogenesis of AS, including genome-wide association studies and cytokine pathways. This study also summarized the current pharmaceutical and surgical treatment with a discussion of future potential therapies.
176
ANKYLOSING SPONDYLITIS AND HL-A 27
D. A. Brewerton, F. Dudley Hart, Anne Nicholls et al. · The Lancet · 1973 · 1.9K citations
Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis
Dominique Baeten, Joachim Sieper, Jürgen Braun et al. · New England Journal of Medicine · 2015 · 1K citations · Full text